These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 28328012)
1. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. Li Z; Xu X; Huang W; Qian H Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012 [TBL] [Abstract][Full Text] [Related]
2. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus. Rani L; Grewal AS; Sharma N; Singh S Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202 [TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes. Sharma N; Bhagat S; Chundawat TS Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025 [TBL] [Abstract][Full Text] [Related]
4. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review. Li Z; Zhou Z; Zhang L Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391 [No Abstract] [Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists. Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923 [TBL] [Abstract][Full Text] [Related]
6. Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status. Eleazu C; Charles A; Eleazu K; Achi N Chem Biol Interact; 2018 Jun; 289():32-39. PubMed ID: 29704509 [TBL] [Abstract][Full Text] [Related]
7. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space. Chen C; Li H; Long YQ Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762 [TBL] [Abstract][Full Text] [Related]
8. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships. Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker. Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709 [TBL] [Abstract][Full Text] [Related]
10. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity. Governa P; Caroleo MC; Carullo G; Aiello F; Cione E; Manetti F Bioorg Med Chem Lett; 2021 Jun; 41():127969. PubMed ID: 33771587 [TBL] [Abstract][Full Text] [Related]
11. An updated patent review of GPR40/ FFAR1 modulators (2020 - present). Ren Q; Fan Y; Yang L; Shan M; Shi W; Qian H Expert Opin Ther Pat; 2023; 33(9):565-577. PubMed ID: 37947382 [TBL] [Abstract][Full Text] [Related]
12. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056 [TBL] [Abstract][Full Text] [Related]
13. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus. Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065 [TBL] [Abstract][Full Text] [Related]
14. Free Fatty Acid Receptors (FFARs): Emerging Therapeutic Targets for the Management of Diabetes Mellitus. Loona DPS; Das B; Kaur R; Kumar R; Yadav AK Curr Med Chem; 2023; 30(30):3404-3440. PubMed ID: 36173072 [TBL] [Abstract][Full Text] [Related]
15. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit. Mancini AD; Poitout V Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916 [TBL] [Abstract][Full Text] [Related]
16. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766 [TBL] [Abstract][Full Text] [Related]
17. Physiology and therapeutics of the free fatty acid receptor GPR40. Huang H; Dai MH; Tao YX Prog Mol Biol Transl Sci; 2014; 121():67-94. PubMed ID: 24373235 [TBL] [Abstract][Full Text] [Related]
18. Modulating GPR40: therapeutic promise and potential in diabetes. Poitout V; Lin DC Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395 [TBL] [Abstract][Full Text] [Related]
19. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes. Bharate SB; Nemmani KV; Vishwakarma RA Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists. Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]